None listed
Conditions
Brief summary
To our knowledge yet no studies compared the efficacy of combined splanchnic nerve blockade and coeliac plexus blockade in pain relief and quality of life due to upper gastro-intestinal (GIT) tumours. The aim of this study was to compare effect for combined block including (splanchnic and celiac ) on quality of analgesia and quality of life versus each technique separately.
Interventions
Group III: for whom splanchnic using (10 ml of 70% alcohol preceded by 2 ml of 2% lidocaine will be injected in each needle, two needles will be used) and celiac blocks (with 20 ml of 70% alcohol preceded by 2.5 ml of 2% lidocaine will be injected in each needle, two needles will be used or 40 ml of alcohol in single needle approach )after failure of pain control with strong opioid medications and then, analgesic requirements will be managed according to severity of pain and WHO analgesic
Group III: for whom splanchnic using (10 ml of 70% alcohol preceded by 2 ml of 2% lidocaine will be injected in each needle, two needles will be used) and celiac blocks (with 20 ml of 70% alcohol preceded by 2.5 ml of 2% lidocaine will be injected in each needle, two needles will be used or 40 ml of alcohol in single needle approach )after failure of pain control with strong opioid medications and then, analgesic requirements will be managed according to severity of pain and WHO analgesic ladder.. The intervention wil be performed once for each patient. Follow up will be extended along patients’ survival.
Sponsors
Mohamed Y. Makharita
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients suffer from visceral pain originating from in-operable abdominal cancer (originated from the upper abdominal viscera, from the stomach to the proximal transverse colon) reporting VAS equal to or greater than 7 after failure of strong opioids analgesics (3rd step of WHO analgesic ladder
Exclusion criteria
Patients have INR >1.5 or platelet count <50,000,infection at the site of needle entry, persistent hypotension, ascites or whom receive previous neurolytic block or have psychiatric illness or whom declines to participate will be excluded from the study.
Outcome results
None listed